NIKKEI 225
39,081.49 +464.39 (+1.20%) HANG SENG
18,862.07 -333.53 (-1.74%) CRUDE OIL
76.97 -0.60 (-0.77%) GOLD FUTURES
2,370.80 -22.10 (-0.92%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,521.63 -351.04 (-0.64%)
Nuvalent, Inc. (NUVL)
After hours:
| Previous close | 69.73 |
| Open | 69.73 |
| Bid | 69.78 x 100 |
| Ask | 70.05 x 100 |
| Day's range | 69.34 - 71.00 |
| 52-week range | 38.14 - 89.39 |
| Volume | |
| Avg. volume | 482,680 |
| Market cap | 4.507B |
| Beta (5Y monthly) | 1.35 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 101.25 |
PR NewswireNuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have been previously treated with two or more ALK tyrosine kinase inhibitors (TKIs).
- PR Newswire
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline progress, reiterated key anticipated milestones, and reported first quarter 2024 financial results.
ZacksWhy Earnings Season Could Be Great for Nuvalent (NUVL)
Nuvalent (NUVL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
